ASCO 2024: Latest Data in Melanoma

home / post-conference-perspectives / asco-2024-latest-data-in-melanoma

Evan J. Lipson, MD, from Johns Hopkins University School of Medicine contributes key updates in melanoma treatment presented at ASCO 2024 in Chicago, Illinois.

EP. 1: ASCO 2024: Addressing Unmet Needs in Melanoma Treatment and Management

July 10th 2024

Key opinion leaders analyze unmet needs and emerging trends in melanoma treatment based on findings presented at ASCO 2024.

Watch

EP. 2: Key Findings from the NADINA Trial at ASCO 2024

July 10th 2024

Dr Lipson continues his discussion as he highlights significant results from the NADINA trial.

Watch

EP. 3: ASCO 2024: Impact of RELATIVITY-047 on Metastatic Melanoma Management

July 10th 2024

Results from the RELATIVITY-047 study on the melanoma landscape are evaluated by Dr Evan Lipson.

Watch

EP. 4: ASCO 2024 Highlights: Long-Term Data and the Future of Combination Therapies in Melanoma

July 13th 2024

Dr Lipson provides insights surrounding combination therapies in melanoma management.

Watch

EP. 5: Highlights from ASCO 2024: Individualized Neoantigen Therapy in Melanoma

July 13th 2024

Considerations for neoantigen therapy tailored to specific patient needs is discussed by Dr Lipson.

Watch

EP. 6: ASCO 2024: Emerging Data on Brenetafusp (IMC-F106C) ImmTAC Bispecific in Melanoma

July 29th 2024

Key opinion leaders analyze unmet needs and emerging trends in melanoma treatment based on findings presented at ASCO 2024.

Watch

EP. 7: Melanoma Research Beyond ASCO 2024: Upcoming Advances and Insights

Watch

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777